Science· 2015Q1

Neoantigens in cancer immunotherapy

Ton N. Schumacher, Robert D. Schreiber

Short summary

Recognition of patient-specific neoantigens, arising from tumor mutations, is a key driver of clinical cancer immunotherapy efficacy.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

OncologyMedicine